How to Get Tresiba (Insulin Degludec) in Tennessee

What Is Tresiba and Why Do Tennessee Patients Request It?

Insulin degludec (Tresiba) is an ultra-long-acting basal insulin with a half-life exceeding 25 hours and an action duration beyond 42 hours, giving it the longest duration profile of any basal insulin currently on the U.S. market. [1] Tennessee has a high burden of diabetes: the CDC estimates that 14.2% of Tennessee adults have diagnosed diabetes, compared with the national average of 11.6%. [2] That prevalence creates high demand for modern basal insulins with favorable safety profiles.

The DEVOTE trial (N=7,637, NEJM 2017) compared insulin degludec U-100 with insulin glargine U-100 in adults with type 2 diabetes at high cardiovascular risk. Degludec produced a 53% lower rate of severe hypoglycemia (1.48 vs. 3.28 events per 100 patient-years of exposure, P<0.001) without sacrificing glycemic control. [3] That hypoglycemia advantage is the most common clinical reason Tennessee providers switch patients from glargine or detemir to degludec.

The FDA approved the 100 units/mL (Tresiba U-100) and 200 units/mL (Tresiba U-200) formulations in September 2015. [4] Both require a prescription and are classified as prescription-only drugs under Tennessee Code Annotated §53-10-101.

Tennessee Prescribing Authority: Who Can Write Your Tresiba Prescription?

Any licensed Tennessee prescriber with DEA and state pharmacy board authority can prescribe Tresiba. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs), provided they hold a current Tennessee controlled substances certificate or the equivalent for Schedule V and non-controlled drugs. Insulin is not a controlled substance, so the prescribing threshold is lower than for most hormone therapies.

Tennessee NPs operating under a collaborative practice agreement with a supervising physician may prescribe insulin independently in most outpatient telehealth and clinical settings. [5] Tennessee PAs also prescribe insulin under a supervision agreement. The American Diabetes Association's 2024 Standards of Care state: "Clinician-led diabetes self-management education and support are associated with improved clinical outcomes and reduced costs and should be reimbursed by third-party payers." [6] That guideline endorses team-based prescribing, which is the structure most Tennessee telehealth platforms use.

Endocrinologists, PCPs, internal medicine physicians, and family medicine providers all routinely prescribe Tresiba. You do not need to see an endocrinologist specifically unless your plan's prior authorization (PA) process requires specialist documentation.

Telehealth Prescribing for Tresiba in Tennessee

Tennessee permits telehealth prescribing of non-controlled medications, including insulin, to established patients and, under specific protocols, to new patients undergoing a synchronous (real-time audio/video) evaluation. [5] A prescriber may not issue an insulin prescription solely from a telephone call with no video component under current Tennessee telemedicine guidelines.

The typical telehealth workflow for Tresiba in Tennessee involves four steps. First, you complete an intake form covering your diabetes diagnosis, current insulin regimen, most recent A1C, and any hypoglycemia history. Second, a licensed Tennessee provider reviews your labs and conducts a synchronous video visit (usually 20 to 30 minutes for a new patient, 10 to 15 minutes for a follow-up). Third, the provider sends a Tresiba e-prescription to your preferred Tennessee pharmacy or to a licensed mail-order pharmacy that ships to Tennessee. Fourth, you receive your medication, typically within three to seven business days.

A 2022 analysis published in JAMA Internal Medicine found that telehealth visits for diabetes management produced comparable A1C reductions to in-person care at six months (mean A1C reduction 0.9 percentage points vs. 0.8 percentage points, P=0.41). [7] That parity supports telehealth as a legitimate first-access pathway for Tresiba in Tennessee.

Labs and Documentation Required Before Starting Tresiba in Tennessee

Most Tennessee providers require a current A1C (drawn within the past 90 days) before prescribing Tresiba. Additional labs that support safe prescribing include a basic metabolic panel to assess renal function (degludec is renally cleared in part), a fasting glucose, and, for patients over 45 or with cardiovascular risk factors, a lipid panel. [8]

The American Association of Clinical Endocrinology (AACE) 2023 Diabetes Algorithm recommends that providers document baseline renal function before initiating any basal insulin because dosing adjustments may be needed when eGFR falls below 45 mL/min/1.73 m². [9] Tennessee telehealth platforms that prescribe insulin will generally request lab results from your existing provider or order labs through a partnered patient service center such as Quest or LabCorp before issuing a prescription.

You should bring or upload the following when requesting Tresiba through any Tennessee provider. A photo ID with Tennessee address, your current diabetes medication list, your most recent A1C result with date, a list of previous insulins tried (relevant for PA purposes), and your insurance card if you plan to use insurance.

Prior Authorization for Tresiba in Tennessee: What Commercial Plans Require

Prior authorization is required by the majority of Tennessee commercial health plans for Tresiba. BlueCross BlueShield of Tennessee, UnitedHealthcare Tennessee, Cigna, and Aetna all classify Tresiba as a non-preferred brand on most formulary tiers as of 2025, meaning PA is required before they will cover it. [10]

Standard PA criteria across most Tennessee commercial plans include documentation of an inadequate response or intolerance to at least one preferred basal insulin (usually insulin glargine U-100 or biosimilars), current A1C greater than 7.0% on the prior insulin, and a clinical note explaining the medical necessity for switching. For patients with documented severe hypoglycemia on glargine or detemir, the DEVOTE data (53% lower severe hypoglycemia rate) provides a strong clinical rationale your provider can cite directly in the PA letter. [3]

Tennessee Medicaid (TennCare) covers Tresiba for members with type 1 diabetes. TennCare does not currently cover Tresiba for members with type 2 diabetes, as the state's preferred drug list designates insulin glargine products as the first-line basal insulin for type 2. Providers may submit a PA appeal citing clinical necessity, but approval rates for type 2 TennCare members are low.

PA decisions typically arrive within 72 hours for standard reviews and 24 hours for urgent requests under Tennessee's prompt-payment and PA processing rules. [11]

How to Transfer an Existing Tresiba Prescription to a Tennessee Pharmacy

Tennessee law permits pharmacists to transfer a non-controlled prescription between pharmacies one time, or unlimited times if both pharmacies are part of the same chain (e.g., CVS to CVS, Walgreens to Walgreens). [12] Because insulin is not a controlled substance, the transfer process is straightforward.

To transfer your Tresiba prescription from an out-of-state pharmacy to a Tennessee pharmacy, call your new Tennessee pharmacy with the name of the prescribing provider, the original pharmacy's phone number, and the prescription number if available. The receiving pharmacist contacts the original pharmacy directly. The process takes less than one business day in most cases.

If you are relocating to Tennessee from another state and your Tresiba prescription was written by an out-of-state provider, you have two options. You may transfer the existing prescription if it has refills remaining, or you may establish care with a Tennessee-licensed provider (in-person or telehealth) who can issue a new prescription. Some Tennessee telehealth platforms can see out-of-state patients who have recently moved and issue a bridge prescription within the same business day, provided you have recent labs on file.

Tennessee Pharmacies That Stock Tresiba

Tresiba U-100 FlexTouch pens (3 mL, 100 units/mL) and U-200 FlexTouch pens (3 mL, 200 units/mL) are stocked at most major Tennessee pharmacy chains. These include CVS, Walgreens, Kroger Pharmacy, Publix Pharmacy, and independent pharmacies in metro areas including Nashville, Memphis, Knoxville, Chattanooga, and Clarksville. Rural Tennessee pharmacies may need 24 to 48 hours to order stock if they do not carry it routinely.

The retail cash price of Tresiba without insurance ranges from approximately $280 to $360 per FlexTouch pen in Tennessee as of mid-2025. Novo Nordisk's My$99Insulin program caps the out-of-pocket cost at $99 per 90-day supply for uninsured or underinsured patients who meet eligibility criteria. [13] GoodRx and similar discount programs may reduce costs to $230, $270 per pen at select Tennessee pharmacies.

Mail-order pharmacies licensed in Tennessee, including CVS Caremark, Express Scripts, and Optum Rx, generally offer a 90-day supply for a single co-pay tier, which lowers per-dose cost for insured patients.

503A Compounding Pharmacies and Insulin Degludec in Tennessee

Tennessee-licensed 503A compounding pharmacies may prepare insulin degludec formulations for individual patients when a valid prescription is presented and a commercially available product is deemed clinically inappropriate for that specific patient. [14] 503A pharmacies compound for individual patients (not in bulk), so each preparation requires a patient-specific prescription from a licensed Tennessee provider.

The FDA notes that compounded insulin products are not AB-rated equivalents to FDA-approved Tresiba and have not undergone the same clinical testing for potency, sterility, and stability. [15] For most Tennessee patients, the commercially manufactured Tresiba FlexTouch is preferred unless the patient has a documented allergy to an inactive ingredient in the commercial formulation or requires a non-standard concentration.

If a Tennessee 503A pharmacy ships insulin degludec to you, it must hold an active Tennessee Board of Pharmacy non-resident pharmacy permit or operate from within Tennessee. Verify licensure at the Tennessee Board of Pharmacy online registry before accepting any compounded insulin shipment.

Tresiba Dosing Basics for Tennessee Patients Starting Therapy

Tresiba is injected subcutaneously once daily. The approved starting doses are 10 units once daily for insulin-naive adults with type 2 diabetes and a weight-based calculation (0.1, 0.2 units/kg/day) for type 1 adults. [1] Dose titration targets a fasting glucose of 80 to 130 mg/dL per ADA 2024 Standards of Care. [6]

The flexible dosing interval (±8 hours from the usual injection time) is a clinically meaningful feature for shift workers and patients with irregular schedules, a common scenario in Tennessee's manufacturing and healthcare workforce. A dedicated pharmacokinetic study confirmed that degludec's flat and stable pharmacodynamic profile is maintained even when consecutive doses are given 8 hours apart, versus the labeled 24-hour interval. [16]

Injection sites include the abdomen, thigh, or upper arm. Rotate sites within the same region to minimize lipohypertrophy. Tresiba should not be diluted or mixed with other insulins, unlike NPH.

Clinical Outcomes Data Tennessee Providers Reference Most Often

Beyond DEVOTE, two additional trials inform Tennessee prescribing decisions for degludec.

SWITCH 1 (N=501, type 1 diabetes) found that patients crossing over from glargine U-100 to degludec experienced a 35% reduction in overall symptomatic hypoglycemia (rate ratio 0.65 to 95% CI 0.54, 0.78, P<0.001) during the maintenance period. [17] SWITCH 2 (N=721, type 2 diabetes) showed a 30% reduction in overall symptomatic hypoglycemia with degludec versus glargine U-100 (rate ratio 0.70 to 95% CI 0.61, 0.80, P<0.001). [18]

The FDA-approved label states that Tresiba has been studied in adults and pediatric patients aged 1 year and older with type 1 diabetes and in adults with type 2 diabetes. [4] Pediatric use in Tennessee follows the same prescribing pathway as adult use, though most pediatric endocrinologists in the state (concentrated at Vanderbilt Children's and Le Bonheur in Memphis) manage dosing adjustments in children under 12 directly.

Cardiovascular Safety: The DEVOTE Trial Explained

DEVOTE was a multicenter, randomized, double-blind, treat-to-target cardiovascular outcomes trial. Investigators enrolled 7,637 adults with type 2 diabetes at high cardiovascular risk across 20 countries and followed them for a median of 2.0 years. The primary endpoint was the first occurrence of a major adverse cardiovascular event (MACE): cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. [3]

Degludec was non-inferior to glargine U-100 for MACE (HR 0.91 to 95% CI 0.78, 1.06, P<0.001 for non-inferiority), confirming cardiovascular safety. The pre-specified secondary endpoint of severe hypoglycemia favored degludec significantly, with 1.48 events per 100 patient-years versus 3.28 events per 100 patient-years for glargine (rate ratio 0.40, P<0.001). [3]

Tennessee cardiologists and endocrinologists co-managing patients post-MI or with heart failure frequently cite DEVOTE when selecting a basal insulin, because reducing severe hypoglycemia is itself a cardiovascular risk-reduction strategy: each severe hypoglycemic episode is associated with a roughly 2-fold increase in cardiovascular mortality risk in high-risk type 2 patients. [19]

Step-by-Step: Getting Tresiba Through a Tennessee Telehealth Platform

The sequence below reflects the current standard workflow on HealthRX and comparable Tennessee-licensed telehealth platforms.

Step 1. Create your account and complete the intake form (10 to 15 minutes). Enter your diabetes diagnosis date, type (1 or 2), current medications, and most recent A1C. Upload any labs dated within the past 90 days.

Step 2. Schedule a synchronous video visit. Most platforms offer same-day or next-business-day appointments. The visit runs 20 to 30 minutes for new patients.

Step 3. The provider reviews your history and confirms Tresiba is appropriate. If PA is likely required, the provider's care team begins the PA process immediately after the visit.

Step 4. The e-prescription is transmitted to your chosen Tennessee pharmacy. Standard processing takes 2 to 4 hours; prior authorization adds 1, 3 business days.

Step 5. Pick up or receive delivery. Same-day pickup is available at most chain pharmacies in Tennessee metro areas. Mail-order delivery to any Tennessee address takes 2, 5 business days.

Step 6. Follow-up check-in at 4 weeks. A fasting glucose log reviewed by your telehealth provider guides any dose titration. ADA guidelines recommend titrating basal insulin by 2 units every 3 days until fasting glucose is within target. [6]